Cardiovascular complications from anthracycline-based chemotherapy (Anth-bC) and other potentially cardiotoxic cancer therapies are a leading cause of morbidity and mortality for survivors of lymphoma, the 5th most common cancer in North America. The objective of this to reduce cancer treatment related CV morbidity by performing and testing a patient-centered, tailored physical activity intervention (PAI) designed to prevent declines in exercise capacity, cardiovascular performance, cognitive function, and quality of life in patients receiving Anth-bC and other potentially cardiotoxic cancer therapies for lymphoma.